Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/26/22
End: 06/30/25
Due: 06/30/26
Phase: N/A
Priority: Normal
Start: 12/09/24
End: 04/30/27
Due: 04/30/28
Phase: N/A
Priority: Normal
Start: 05/31/25
End: 12/31/28
Due: 12/31/29
Phase: N/A
Priority: Normal
Start: 10/22/18
End: 01/31/28
Due: 01/31/29
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma | NCT05239182 | Anwaar Saeed | user2@example.com | None | 2022-01-26 | 2025-06-30 | 2026-06-30 | - | - | 2025-07-14 |
| Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) | NCT06698250 | Anwaar Saeed | user2@example.com | None | 2024-12-09 | 2027-04-30 | 2028-04-30 | - | - | 2025-07-14 |
| 9-ING-41 Combined with Retifanlimab, Plus Modified FOLFIRINOX for Patients with Advanced Pancreatic Adenocarcinoma (RiLEY) | NCT06896188 | Anwaar Saeed | user2@example.com | None | 2025-05-31 | 2028-12-31 | 2029-12-31 | - | - | 2025-07-14 |
| Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies | NCT03539822 | Anwaar Saeed | user2@example.com | None | 2018-10-22 | 2028-01-31 | 2029-01-31 | - | - | 2025-07-14 |